← Dynavax Technologies Corporation (DVAX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Dynavax Technologies Corporation (DVAX)
Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-29 (est.)
Phase 2
Pipeline
9
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Dynavax Technologies (DVAX) is a commercial-stage vaccine company with approximately 405 employees and a $1.82B market cap, anchored by HEPLISAV-B, its approved hepatitis B vaccine now being studied in Phase 3 for chronic kidney disease patients. Revenue has normalized sharply from a 2022 COVID-era peak ($723M) to a more sustainable but declining base ($277M in 2024), and the company returned to profitability in 2024 on $27M net income.
The catalyst path
- 2027-01-29 (est.)Phase 2 · rF1V-1018imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Z-1018 | Phase 2 | Shingles |
| HEPLISAV-B | Phase 3 | Chronic Kidney Disease |
| HEPLISAV | Phase 3 | Hepatitis B |
| Engerix-B | Phase 3 | Hepatitis B |
| Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate | Phase 2 | Rhinitis, Allergic, Seasonal |
| rF1V-1018 | Phase 2 | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis |
| rF1V vaccine | Phase 2 | Plague, Pneumonic |
| Fendrix | Phase 3 | End Stage Renal Disease |
| Rituxan | Phase 2 | Non-Hodgkin's Lymphoma |
Price & technical context
3-month
+41.0%
6-month
+46.5%
12-month
+24.5%
52-wk range
$9.36–$15.72
vs 50-day MA
+12.5%
vs 200-day MA
+38.3%
Realized vol
49.9%
Max drawdown
-35.0%
Daily closes through 2026-02-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DVAX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.